Kindlin‑2 suppresses cervical cancer cell migration through AKT/mTOR‑mediated autophagy inductionGuangteng Wu, Desheng Yao|Oncology Reports|2020Cited by 12
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancerJung‐Yun Lee, Lingying Wu, Jeong‐Won Lee et al.|Gynecologic Oncology|2025Cited by 7
Development and External Validation of a Novel Model for Predicting Postsurgical Recurrence and Overall Survival After Cytoreductive R0 Resection of Epithelial Ovarian CancerQiaqia Li, Jundong Li, Yinghong Deng et al.|Frontiers in Oncology|2022Cited by 4